Allogene Therapeutics, Inc. (ALLO) Insider Ownership

Historic Insider Ownership Trends

According to recent filings covering the 90 days ending February 07, 2026, the three most significant insider holders at Allogene Therapeutics are President And Ceo David D Chang (5.19Mn shares), Director Arie Belldegrun (3.96Mn shares), Chief Financial Officer Geoffrey M. Parker (1.25Mn shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares Report Date
David D Chang President And Ceo 5,185,862 04 Feb, 2026
Arie Belldegrun 3,960,953 28 Jan, 2025
Geoffrey M. Parker Chief Financial Officer 1,252,795 04 Feb, 2026
Eric Thomas Schmidt Chief Financial Officer 862,439 24 Mar, 2023
Alison Moore Chief Technical Officer 672,731 24 Mar, 2023
Zachary Roberts Evp Of R&D 581,166 04 Feb, 2026
Earl Martin Douglas Svp And General Counsel 564,948 04 Feb, 2026
Veer Bhavnagri General Counsel 556,049 16 Mar, 2023
Rafael Amado Evp Of R&D 541,946 11 Oct, 2022
Joshua A Kazam 350,763 22 Dec, 2025
Franz B Humer 307,507 09 Dec, 2024
Owen N. Witte 292,832 15 Jun, 2023
Timothy L. Moore Chief Technical Officer 250,713 05 Feb, 2025
Benjamin Machinas Beneski Svp And Chief Technical Officer 210,172 04 Feb, 2026
Vicki L Sato 162,575 07 Jun, 2024
Lillian Smith Vp And Corporate Counsel 140,390 05 Apr, 2023
Annie Yoshiyama Svp And Finance 130,322 04 Feb, 2026
Deborah M. Messemer 107,431 12 Jun, 2025
Yinlin Jack Chen Svp And Finance 88,881 14 Aug, 2023
Stephen Mayo 25,328 09 Aug, 2023

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
02 Feb, 2026 Earl Martin Douglas Common Stock D 22,900 $1.76 564,948 D S
02 Feb, 2026 Geoffrey M. Parker Common Stock D 24,001 $1.76 1,252,795 D S
02 Feb, 2026 David D Chang Common Stock D 95,269 $1.80 5,185,862 D S
02 Feb, 2026 Annie Yoshiyama Common Stock D 4,167 $1.72 130,322 D S
02 Feb, 2026 Zachary Roberts Common Stock D 35,700 $1.77 581,166 D S
02 Feb, 2026 Benjamin Machinas Beneski Common Stock D 7,549 $1.73 210,172 D S
21 Jan, 2026 Zachary Roberts Common Stock D 26,269 $1.56 616,866 D S
18 Dec, 2025 Joshua A Kazam Common Stock A 47,700 $0.00 350,763 D M
18 Dec, 2025 Joshua A Kazam - - 350,763 D
17 Nov, 2025 Benjamin Machinas Beneski Common Stock D 786 $1.22 217,721 D S
21 Oct, 2025 Geoffrey M. Parker Common Stock D 36,744 $1.26 1,276,796 D S
10 Jun, 2025 Deborah M. Messemer Common Stock D 36,885 $1.42 107,431 D S
10 Jun, 2025 Deborah M. Messemer - - 107,431 D
21 Apr, 2025 Annie Yoshiyama Common Stock D 9,601 $1.41 130,663 D S
21 Apr, 2025 Annie Yoshiyama - - 130,663 D
14 Mar, 2025 David D Chang Common Stock D 46,668 $1.96 5,276,569 D S
14 Mar, 2025 Benjamin Machinas Beneski Common Stock D 5,488 $1.98 218,507 D S
01 Mar, 2025 Benjamin Machinas Beneski - - 223,995 D
01 Mar, 2025 Benjamin Machinas Beneski Common Stock A 31,755 $0.00 223,995 D A
18 Feb, 2025 Deborah M. Messemer Common Stock D 13,313 $2.43 144,316 D S